TAGI Pharma Announces Exclusive Marketing Rights Agreement for Alendronate Sodium Oral Solution, 70mg/75ml x 4 Pack Unit of Use
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SOUTH BELOIT, Ill., April 30, 2013 (GLOBE NEWSWIRE) -- TAGI Pharma, Inc., a specialty pharmaceutical company and subsidiary of Precision Dose, Inc., announced today the signing of an exclusive marketing rights agreement to market and sell the approved ANDA product, Alendronate Sodium Oral Solution, 70mg/75mL in the United States and its territories, possessions and protectorates.
Help employers find you! Check out all the jobs and post your resume.
SOUTH BELOIT, Ill., April 30, 2013 (GLOBE NEWSWIRE) -- TAGI Pharma, Inc., a specialty pharmaceutical company and subsidiary of Precision Dose, Inc., announced today the signing of an exclusive marketing rights agreement to market and sell the approved ANDA product, Alendronate Sodium Oral Solution, 70mg/75mL in the United States and its territories, possessions and protectorates.
Help employers find you! Check out all the jobs and post your resume.